These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35233567)

  • 1. Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant.
    Chen J; Wei GW
    Res Sq; 2022 Feb; ():. PubMed ID: 35233567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant.
    Chen J; Wei GW
    ArXiv; 2022 Feb; ():. PubMed ID: 35169598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant.
    Chen J; Wei GW
    J Phys Chem Lett; 2022 May; 13(17):3840-3849. PubMed ID: 35467344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The First Identification in Italy of SARS-CoV-2 Omicron BA.4 Harboring KSF141_del: A Genomic Comparison with Omicron Sub-Variants.
    Peronace C; Tallerico R; Colosimo M; Fazio M; Pasceri F; Talotta I; Panduri G; Pintomalli L; Oteri R; Calantoni V; Fiorillo MT; Caroleo MC; Curcio R; Dolce V; Cione E; Minchella P
    Biomedicines; 2022 Jul; 10(8):. PubMed ID: 36009386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent Laplacian projected Omicron BA.4 and BA.5 to become new dominating variants.
    Chen J; Qiu Y; Wang R; Wei GW
    Comput Biol Med; 2022 Dec; 151(Pt A):106262. PubMed ID: 36379191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance.
    Chen J; Wang R; Gilby NB; Wei GW
    J Chem Inf Model; 2022 Jan; 62(2):412-422. PubMed ID: 34989238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
    Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
    Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
    Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
    J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance.
    Chen J; Wang R; Gilby NB; Wei GW
    ArXiv; 2021 Dec; ():. PubMed ID: 34873578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
    Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
    Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topological AI forecasting of future dominating viral variants.
    Wei GW
    ArXiv; 2022 Sep; ():. PubMed ID: 36118666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.
    Strasser ZH; Greifer N; Hadavand A; Murphy SN; Estiri H
    JAMA Netw Open; 2022 Oct; 5(10):e2238354. PubMed ID: 36282501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
    Roe TL; Brady T; Schuko N; Nguyen A; Beloor J; Guest JD; Aksyuk AA; Tuffy KM; Zhang T; Streicher K; Kelly EJ; Kijak GH
    Microbiol Spectr; 2023 Mar; 11(2):e0033323. PubMed ID: 36877050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity.
    Zhou Y; Zhi H; Teng Y
    J Med Virol; 2023 Jan; 95(1):e28138. PubMed ID: 36097349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omicron (B.1.1.529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world? -An overview of current evidence and counteracting strategies.
    Sah R; Rais MA; Mohanty A; Chopra H; Chandran D; Bin Emran T; Dhama K
    Int J Surg Open; 2023 Jun; 55():100625. PubMed ID: 37255735
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.